Cyclacel Pharmaceuticals Ownership | Who Owns Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals Ownership Summary
Cyclacel Pharmaceuticals is owned by 0.23% institutional investors, 0.99% insiders, and 98.78% retail investors. Fidelity Nasdaq Composite Index is the top mutual fund, with 0.03% of its assets in Cyclacel Pharmaceuticals shares.
CYCC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Cyclacel Pharmaceuticals | 0.23% | 0.99% | 98.78% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 1 | - | 4,935 | - | - | - | 1 | - | - | - |
| Sep 30, 2023 | 20 | -13.04% | 1,134,910 | -45.03% | 9 | 3.34% | 6 | 20.00% | 5 | - |
| Jun 30, 2023 | 23 | -11.54% | 2,064,450 | -17.83% | 16 | 4.10% | 5 | -16.67% | 5 | -28.57% |
| Mar 31, 2023 | 26 | -13.33% | 2,512,518 | 2.28% | 20 | 4.21% | 6 | -57.14% | 7 | - |
| Dec 31, 2022 | 30 | 15.38% | 2,456,591 | 5.48% | 21 | 6.10% | 14 | -22.22% | 7 | 75.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Nasdaq Composite Index | 709.00 | 0.03% | - |
| Fidelity Extended Market Index | 8.96K | 0.00% | - |
| Northern Trust Extended Eq Market Idx | 380.00 | 0.00% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 5.80K | 0.00% | - |
| Spartan Extended Market Index Pool E | 169.00 | 0.00% | - |
| NT US Market Cap Idx Fd - L | 44.00 | 0.00% | - |
| NT Ext Eq Mkt Indx Fd DC Lend T3 | 91.00 | 0.00% | 91.00 |
| NT Ext Eq Mkt Indx Fd DC Lend T4 | 91.00 | 0.00% | 91.00 |
| Fidelity Series Total Market Index | 1.66K | 0.00% | - |
| Northern Trust Wilshire 5000 | 44.00 | 0.00% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 26, 2025 | Lazar David E. | Interim CEO | Sell | $5.51M |
| Dec 21, 2023 | McBarron Paul | See Remarks | Buy | $6.25K |
| Dec 21, 2023 | McBarron Paul | See Remarks | Buy | $6.02K |
| Dec 21, 2023 | Rombotis Spiro George | President and CEO | Buy | $19.36K |
| Dec 21, 2023 | Rombotis Spiro George | President and CEO | Buy | $20.12K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | 1 |
| 2024 Q1 | - | - |
| 2023 Q4 | 8 | - |
| 2023 Q2 | - | - |
| 2023 Q1 | - | - |
CYCC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools